# KRYSTAL 2 (NCT04330664)

> Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

No report yet. It can be ordered.

- Drugs tested: adagrasib plus TNO155
- Indication: KRAS G12C-mutated advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04330664
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
- Interventions: MRTX849; TNO155
- Enrollment: 86
- Primary outcome: Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.
- Primary outcome: Evaluate the pharmacokinetics of MRTX849 and TNO155

## Indexed commentary on KRYSTAL 2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=krystal-2-nct04330664